Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Matthew B.B. Yurgelun

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6184-9273; OpenAlex author ID A5005140127. Sources: ClinicalTrials.gov.

Their work

Papers
23 (first author 2, last author 4)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
1
Collaborators
107
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper, 1 trial · 2018: 1 paper · 2019: 5 papers · 2020: 1 paper · 2021: 3 papers · 2022: 3 papers · 2023: 3 papers, 1 trial · 2024: 2 papers · 2025: 1 paper · 2026: 2 papers

Papers 23

  1. A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2. Co-author DOI 10.1158/1078-0432.ccr-24-3766↗
  2. Immune and stromal features of durable complete response to radiation and dual immune checkpoint blockade in pancreatic cancer Co-author DOI 10.64898/2026.08.06.26359422↗
  3. Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreat… Co-author DOI 10.1200/po-25-00332↗
  4. A Randomized Trial of Two Remote Health Care Delivery Models on the Uptake of Genetic Testing and Impact on Patient-Reported Psychological Outcomes in Families… Co-author DOI 10.1053/j.gastro.2024.01.042↗
  5. Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the T… Co-author DOI 10.1158/2326-6066.cir-23-1073↗
  6. Adipose tissue and skeletal muscle wasting precede clinical diagnosis of pancreatic cancer. Co-author DOI 10.1038/s41467-023-40024-3↗
  7. Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer. Co-author DOI 10.1093/oncolo/oyad002↗
  8. Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-22-3930↗
  9. The Evolving Paradigm of Germline Testing in Pancreatic Ductal Adenocarcinoma and Implications for Clinical Practice. Co-author DOI 10.1016/j.path.2022.05.004↗
  10. Surveillance Imaging in Individuals at High Risk for Pancreatic Cancer: Not a Ceiling, but Rather a Floor Upon Which to Build. Last author DOI 10.1053/j.gastro.2021.12.259↗
  11. Building on More Than 20 Years of Progress in Pancreatic Cancer Surveillance for High-Risk Individuals. Co-author DOI 10.1200/jco.22.01287↗
  12. Novel Models of Genetic Education and Testing for Pancreatic Cancer Interception: Preliminary Results from the GENERATE Study. First author DOI 10.1158/1940-6207.capr-20-0642↗
  13. Implementing Systematic Genetic Counseling and Multigene Germline Testing for Individuals With Pancreatic Cancer. Last author DOI 10.1200/op.20.00678↗
  14. Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after earlier progression on placebo treatment o… Co-author DOI 10.21037/jgo-21-197↗
  15. Correction to: Health Care Provider Perceptions of Caring for Individuals with Inherited Pancreatic Cancer Risk. Last author DOI 10.1007/s13187-019-01671-7↗
  16. Health behaviours and beliefs in individuals with familial pancreatic cancer. Co-author DOI 10.1007/s10689-019-00143-7↗
  17. Family history of cancer, Ashkenazi Jewish ancestry, and pancreatic cancer risk. Co-author DOI 10.1038/s41416-019-0426-5↗
  18. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Co-author DOI 10.1038/s41436-018-0009-5↗
  19. Genetics of Familial and Sporadic Pancreatic Cancer. First author DOI 10.1053/j.gastro.2018.12.039↗
  20. Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion. Co-author DOI 10.1200/jco.18.01489↗
  21. Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Co-author DOI 10.1158/2159-8290.cd-18-0275↗
  22. Germline Testing for Individuals With Pancreatic Cancer: The Benefits and Challenges to Casting a Wider Net. Co-author DOI 10.1200/jco.2017.74.7535↗
  23. Advances in Hereditary Colorectal and Pancreatic Cancers. Last author DOI 10.1016/j.clinthera.2016.03.017↗

Trials 2

  1. Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals Principal investigator NCT06122896↗
  2. Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy Principal investigator NCT03060720↗

Closest collaborators

The 25 strongest of 107 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Brian Matthew Wolpin · 12 shared papers, 2019–2026 · strength 1.68
  2. Kimberly J. Perez · 9 shared papers, 2019–2026 · strength 1.11
  3. James M. Cleary · 7 shared papers, 2021–2026 · strength 1.03
  4. Douglas Adam Rubinson · 8 shared papers, 2019–2026 · strength 0.98
  5. Andrew J. Aguirre · 7 shared papers, 2019–2026 · strength 0.90
  6. Jonathan Andrew Nowak · 7 shared papers, 2019–2026 · strength 0.87
  7. Meghan L. Underhill-Blazey · 6 shared papers, 2016–2024 · strength 0.72
  8. Harshabad Singh · 5 shared papers, 2021–2026 · strength 0.72
  9. Kimmie Ng · 5 shared papers, 2019–2026 · strength 0.67
  10. Leah H. Biller · 4 shared papers, 2023–2026 · strength 0.61
  11. Thomas Adam Abrams · 4 shared papers, 2023–2026 · strength 0.60
  12. Srivatsan Raghavan · 4 shared papers, 2023–2026 · strength 0.59
  13. Sapna Syngal · 5 shared papers, 2019–2024 · strength 0.54
  14. Michael Hayden Rosenthal · 3 shared papers, 2022–2023 · strength 0.51
  15. Michael Goggins · 4 shared papers, 2019–2024 · strength 0.49
  16. Brandon M. Huffman · 3 shared papers, 2024–2026 · strength 0.48
  17. Colin D. Weekes · 3 shared papers, 2023–2026 · strength 0.47
  18. Geoffrey Ira Shapiro · 3 shared papers, 2021–2026 · strength 0.43
  19. Anirban Maitra · 3 shared papers, 2021–2024 · strength 0.43
  20. Florencia M. McAllister · 3 shared papers, 2021–2024 · strength 0.43
  21. Rishi Surana · 3 shared papers, 2023–2025 · strength 0.41
  22. Andrea J. Bullock · 3 shared papers, 2019–2026 · strength 0.40
  23. Chen Yuan · 4 shared papers, 2019–2023 · strength 0.39
  24. Mary Linton B. Peters · 2 shared papers, 2025–2026 · strength 0.34
  25. ANDREA C Enzinger · 2 shared papers, 2025–2026 · strength 0.34

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.